- ProMIS Neurosciences (NASDAQ:PMN), a clinical-stage biotech stock focused on neurodegenerative diseases, has been granted the U.S. Food and Drug Administration’s Fast-Track Designation for PMN310, its lead monoclonal antibody treatment for Alzheimer’s disease
- The treatment is designed to offer a more targeted response compared to legacy options, reducing common side effects including brain swelling and bleeding known as amyloid-related imaging abnormalities (ARIA)
- ProMIS is a clinical-stage biotechnology stock focused on developing treatments against neurodegenerative and other misfolded protein diseases
- The Alzheimer’s stock is up by 213.70 per cent on the news trading at US$1.38 as of 11:04 am ET, but has given back 28.47 per cent year-over-year and 85.15 per cent since 2020
ProMIS Neurosciences (NASDAQ:PMN), a clinical-stage biotech stock focused on…
